The Latest Advancements in the Treatment of CLL

In this MEDtalk, Professor John Gribben from Barts Cancer Institute explores the latest advancements in the treatment of Chronic Lymphocytic Leukemia (CLL). He discusses the paradigm shift from conventional chemotherapy to targeted therapies and delves into the most recent strategies for CLL treatment. This includes an exploration of pioneering agents such as pirtobrutinib, the promising capabilities of bi-specific antibodies, and the progressive role of CAR-T therapy in the evolving CLL treatment landscape.